|
|
|
|
Vol. 60, Issue 4, 674-680, October 2001
The Cancer Institute of New Jersey, University of Medicine and
Dentistry of New Jersey/Robert Wood Johnson Medical School, Departments
of Medicine and Pharmacology, New Brunswick, New Jersey
Resistance to multiple, unrelated cancer chemotherapeutic drugs
can be mediated by P-glycoprotein, the MDR1 gene
product. Numerous substances, including chemotherapeutic drugs, heavy
metals, growth factors, activated oncogenes, or changes in temperature increase MDR1 gene expression. Because several of these
factors regulate cellular function through the activation of
phospholipase C (PLC), we postulated that PLC-mediated signaling could
be central to regulating the expression of MDR1.
Transfection of NIH 3T3 cells with a pMJ30-PLC-
1 expression vector
increased the activity of the MDR1 promoter by 2- to
10-fold. PLC-mediated activation required a region between
106 and
99 of the MDR1 promoter. Treatment of cotransfected
cells with platelet-derived growth factor further enhanced the activity
of the MDR1 promoter. The stimulatory effect of PLC on
the MDR1 promoter was increased by cotransfection with constitutively active v-raf and was blocked by the dominant-negative mutant, c-Raf-C4. The activity of mitogen-activated protein kinase (MAPK) was also increased in PLC-
1-transfected cells. Furthermore, PD-98059 and U0126, two MAPK inhibitors, blocked PLC-
1-induced expression of MDR1. The results of Northern blot
analysis showed that activation of PLC by heat shock and growth factors
increased expression of endogenous MDR1 mRNA in human renal carcinoma
cells. These effects were blocked by inhibitors of the PLC-MAPK
pathway. In summary, our results indicate for the first time that
activation of PLC by a variety of cellular stimuli can regulate the
expression of MDR1 and that the transcriptional
modulation of MDR1 expression by PLC is mediated by the
Raf-MAPK pathway.
This article has been cited by other articles:
![]() |
R. Callaghan, E. Crowley, S. Potter, and I. D. Kerr P-glycoprotein: So Many Ways to Turn It On J. Clin. Pharmacol., March 1, 2008; 48(3): 365 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. T. Buckley, F. Sekiya, Y. J. Kim, S. G. Rhee, and K. K. Caldwell Identification of Phospholipase C-{gamma}1 as a Mitogen-activated Protein Kinase Substrate J. Biol. Chem., October 1, 2004; 279(40): 41807 - 41814. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mahadevan and A. F. List Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies Blood, October 1, 2004; 104(7): 1940 - 1951. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, J.-Y. Wu, W. N. Hait, and J.-M. Yang Regulation of the Stability of P-Glycoprotein by Ubiquitination Mol. Pharmacol., September 1, 2004; 66(3): 395 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wu, W. N. Hait, and J.-M. Yang Small Interfering RNA-induced Suppression of MDR1 (P-Glycoprotein) Restores Sensitivity to Multidrug-resistant Cancer Cells Cancer Res., April 1, 2003; 63(7): 1515 - 1519. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Yang, Z. Xu, H. Wu, H. Zhu, X. Wu, and W. N. Hait Overexpression of Extracellular Matrix Metalloproteinase Inducer in Multidrug Resistant Cancer Cells Mol. Cancer Res., April 1, 2003; 1(6): 420 - 427. [Abstract] [Full Text] [PDF] |
||||